Your browser doesn't support javascript.
loading
Intratumoral delivery of TransCon™ TLR7/8 Agonist promotes sustained anti-tumor activity and local immune cell activation while minimizing systemic cytokine induction.
Zúñiga, Luis Alejandro; Leßmann, Torben; Uppal, Karan; Bisek, Nicola; Hong, Enping; Rasmussen, Caroline E; Karlsson, Jens-Jakob; Zettler, Joachim; Holten-Andersen, Lars; Bang, Kathy; Thakar, Dhruv; Lee, Yu-Chi; Martinez, Salomon; Sabharwal, Simran Singh; Stark, Sebastian; Faltinger, Frank; Kracker, Oliver; Weisbrod, Samuel; Müller, Robin; Voigt, Tobias; Bigott, Kornelia; Tabrizifard, Mohammad; Breinholt, Vibeke Miller; Mirza, Amer M; Rosen, David B; Sprogøe, Kennett; Punnonen, Juha.
Afiliación
  • Zúñiga LA; Ascendis Pharma, Inc., Redwood City, CA, USA.
  • Leßmann T; Ascendis Pharma GmbH, Heidelberg, Germany.
  • Uppal K; Ascendis Pharma, Inc., Redwood City, CA, USA.
  • Bisek N; Ascendis Pharma GmbH, Heidelberg, Germany.
  • Hong E; Ascendis Pharma, Inc., Redwood City, CA, USA.
  • Rasmussen CE; Ascendis Pharma A/S, Hellerup, Copenhagen, Denmark.
  • Karlsson JJ; Ascendis Pharma A/S, Hellerup, Copenhagen, Denmark.
  • Zettler J; Ascendis Pharma GmbH, Heidelberg, Germany.
  • Holten-Andersen L; Ascendis Pharma A/S, Hellerup, Copenhagen, Denmark.
  • Bang K; Ascendis Pharma, Inc., Redwood City, CA, USA.
  • Thakar D; Ascendis Pharma, Inc., Redwood City, CA, USA.
  • Lee YC; Ascendis Pharma, Inc., Redwood City, CA, USA.
  • Martinez S; Ascendis Pharma, Inc., Redwood City, CA, USA.
  • Sabharwal SS; Ascendis Pharma, Inc., Redwood City, CA, USA.
  • Stark S; Ascendis Pharma GmbH, Heidelberg, Germany.
  • Faltinger F; Ascendis Pharma GmbH, Heidelberg, Germany.
  • Kracker O; Ascendis Pharma GmbH, Heidelberg, Germany.
  • Weisbrod S; Ascendis Pharma GmbH, Heidelberg, Germany.
  • Müller R; Ascendis Pharma GmbH, Heidelberg, Germany.
  • Voigt T; Ascendis Pharma GmbH, Heidelberg, Germany.
  • Bigott K; Ascendis Pharma GmbH, Heidelberg, Germany.
  • Tabrizifard M; Ascendis Pharma, Inc., Redwood City, CA, USA.
  • Breinholt VM; Ascendis Pharma A/S, Hellerup, Copenhagen, Denmark.
  • Mirza AM; Ascendis Pharma, Inc., Redwood City, CA, USA.
  • Rosen DB; Ascendis Pharma, Inc., Redwood City, CA, USA.
  • Sprogøe K; Ascendis Pharma A/S, Hellerup, Copenhagen, Denmark. ks@ascendispharma.com.
  • Punnonen J; Ascendis Pharma, Inc., Redwood City, CA, USA.
Cancer Cell Int ; 22(1): 286, 2022 Sep 19.
Article en En | MEDLINE | ID: mdl-36123697
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Cancer Cell Int Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Cancer Cell Int Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos